Veracyte Stock Price To Sales

VCYT Stock

USD 42.95 0.06 0.14%

Veracyte fundamentals help investors to digest information that contributes to Veracyte's financial success or failures. It also enables traders to predict the movement of Veracyte Stock. The fundamental analysis module provides a way to measure Veracyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Veracyte stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	5.54	5.26

Price To Sales Ratio is likely to drop to 5.26 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Veracyte Company Price To Sales Analysis

Veracyte's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Veracyte Price To Sales

7.83 X

Most of Veracyte's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Veracyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Veracyte Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Veracyte is extremely important. It helps to project a fair market value of Veracyte Stock properly, considering its historical fundamentals such as Price To Sales. Since Veracyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Veracyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Veracyte's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Short Term Investments	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Short Long Term Debt	Short Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue
Total Assets		1.0	-0.68	-0.88	0.9	0.97	0.84	0.73	0.81	0.96	0.47	0.87	-0.47	0.97	-0.47	0.99	0.58	0.87	-0.41	0.0	0.79	0.69	0.98	0.9
Total Stockholder Equity	1.0		-0.68	-0.87	0.9	0.97	0.83	0.73	0.8	0.96	0.47	0.87	-0.48	0.97	-0.48	0.99	0.57	0.87	-0.43	-0.02	0.79	0.69	0.98	0.9
Net Debt	-0.68	-0.68		0.69	-0.48	-0.67	-0.52	-0.94	-0.74	-0.56	-0.27	-0.85	0.5	-0.5	0.5	-0.68	-0.7	-0.56	0.47	0.23	-0.61	-0.98	-0.75	-0.42
Retained Earnings	-0.88	-0.87	0.69		-0.75	-0.94	-0.82	-0.75	-0.87	-0.91	-0.4	-0.83	0.19	-0.81	0.19	-0.9	-0.71	-0.73	0.24	-0.13	-0.77	-0.73	-0.87	-0.69
Accounts Payable	0.9	0.9	-0.48	-0.75		0.85	0.78	0.52	0.7	0.91	0.34	0.72	-0.41	0.93	-0.41	0.89	0.31	0.74	-0.34	0.05	0.71	0.45	0.85	0.84
Net Receivables	0.97	0.97	-0.67	-0.94	0.85		0.89	0.75	0.87	0.96	0.51	0.85	-0.33	0.93	-0.33	0.97	0.67	0.87	-0.33	0.07	0.78	0.7	0.96	0.85
Total Liab	0.84	0.83	-0.52	-0.82	0.78	0.89		0.71	0.92	0.84	0.54	0.59	-0.1	0.8	-0.1	0.8	0.66	0.89	-0.13	0.24	0.51	0.54	0.83	0.81
Total Current Assets	0.73	0.73	-0.94	-0.75	0.52	0.75	0.71		0.88	0.62	0.44	0.81	-0.41	0.56	-0.41	0.71	0.78	0.72	-0.4	-0.12	0.59	0.96	0.81	0.51
Common Stock	0.81	0.8	-0.74	-0.87	0.7	0.87	0.92	0.88		0.78	0.52	0.72	-0.19	0.69	-0.19	0.78	0.79	0.82	-0.24	0.09	0.59	0.76	0.83	0.65
Property Plant Equipment	0.96	0.96	-0.56	-0.91	0.91	0.96	0.84	0.62	0.78		0.38	0.81	-0.3	0.96	-0.3	0.97	0.57	0.78	-0.26	0.15	0.79	0.57	0.92	0.85
Short Term Investments	0.47	0.47	-0.27	-0.4	0.34	0.51	0.54	0.44	0.52	0.38		0.41	-0.21	0.42	-0.21	0.4	0.27	0.65	-0.26	-0.1	0.47	0.35	0.5	0.38
Net Tangible Assets	0.87	0.87	-0.85	-0.83	0.72	0.85	0.59	0.81	0.72	0.81	0.41		-0.53	0.79	-0.53	0.9	0.57	0.63	-0.48	-0.14	0.92	0.86	0.9	0.58
Long Term Debt	-0.47	-0.48	0.5	0.19	-0.41	-0.33	-0.1	-0.41	-0.19	-0.3	-0.21	-0.53		-0.43	1.0	-0.45	-0.12	-0.43	0.78	0.64	-0.4	-0.48	-0.53	-0.39
Good Will	0.97	0.97	-0.5	-0.81	0.93	0.93	0.8	0.56	0.69	0.96	0.42	0.79	-0.43		-0.43	0.97	0.44	0.82	-0.37	0.04	0.77	0.52	0.93	0.91
Long Term Debt Total	-0.47	-0.48	0.5	0.19	-0.41	-0.33	-0.1	-0.41	-0.19	-0.3	-0.21	-0.53	1.0	-0.43		-0.45	-0.12	-0.43	0.78	0.64	-0.4	-0.48	-0.53	-0.39
Capital Surpluse	0.99	0.99	-0.68	-0.9	0.89	0.97	0.8	0.71	0.78	0.97	0.4	0.9	-0.45	0.97	-0.45		0.58	0.8	-0.41	0.0	0.84	0.7	0.97	0.85
Deferred Long Term Liab	0.58	0.57	-0.7	-0.71	0.31	0.67	0.66	0.78	0.79	0.57	0.27	0.57	-0.12	0.44	-0.12	0.58		0.62	-0.1	0.13	0.37	0.72	0.63	0.45
Intangible Assets	0.87	0.87	-0.56	-0.73	0.74	0.87	0.89	0.72	0.82	0.78	0.65	0.63	-0.43	0.82	-0.43	0.8	0.62		-0.37	-0.03	0.49	0.61	0.88	0.89
Short Long Term Debt	-0.41	-0.43	0.47	0.24	-0.34	-0.33	-0.13	-0.4	-0.24	-0.26	-0.26	-0.48	0.78	-0.37	0.78	-0.41	-0.1	-0.37		0.91	-0.36	-0.48	-0.46	-0.34
Short Term Debt	0.0	-0.02	0.23	-0.13	0.05	0.07	0.24	-0.12	0.09	0.15	-0.1	-0.14	0.64	0.04	0.64	0.0	0.13	-0.03	0.91		-0.04	-0.23	-0.05	0.03
Net Invested Capital	0.79	0.79	-0.61	-0.77	0.71	0.78	0.51	0.59	0.59	0.79	0.47	0.92	-0.4	0.77	-0.4	0.84	0.37	0.49	-0.36	-0.04		0.62	0.79	0.46
Net Working Capital	0.69	0.69	-0.98	-0.73	0.45	0.7	0.54	0.96	0.76	0.57	0.35	0.86	-0.48	0.52	-0.48	0.7	0.72	0.61	-0.48	-0.23	0.62		0.78	0.44
Capital Stock	0.98	0.98	-0.75	-0.87	0.85	0.96	0.83	0.81	0.83	0.92	0.5	0.9	-0.53	0.93	-0.53	0.97	0.63	0.88	-0.46	-0.05	0.79	0.78		0.85
Current Deferred Revenue	0.9	0.9	-0.42	-0.69	0.84	0.85	0.81	0.51	0.65	0.85	0.38	0.58	-0.39	0.91	-0.39	0.85	0.45	0.89	-0.34	0.03	0.46	0.44	0.85

Click cells to compare fundamentals

Veracyte Price To Sales Historical Pattern

Today, most investors in Veracyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Veracyte's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Veracyte price to sales as a starting point in their analysis.

Veracyte Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Veracyte

Price To Sales Ratio Over Time

Veracyte Price To Sales Ratio

Price To Sales Ratio

5.26

At this time, Veracyte's Price To Sales Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Veracyte has a Price To Sales of 7.8259 times. This is 63.43% lower than that of the Biotechnology sector and 92.05% lower than that of the Health Care industry. The price to sales for all United States stocks is 31.47% higher than that of the company.

Veracyte Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Veracyte's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Veracyte could also be used in its relative valuation, which is a method of valuing Veracyte by comparing valuation metrics of similar companies.

Veracyte is currently under evaluation in price to sales category among its peers.

Veracyte Current Valuation Drivers

We derive many important indicators used in calculating different scores of Veracyte from analyzing Veracyte's financial statements. These drivers represent accounts that assess Veracyte's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Veracyte's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.3B	2.6B	2.8B	1.7B	2.0B	2.1B
Enterprise Value	1.1B	2.3B	2.6B	1.6B	1.8B	1.9B

Veracyte ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Veracyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Veracyte's managers, analysts, and investors.

Environmental

Governance

Social

Veracyte Fundamentals

	Return On Equity	-0.0083
	Return On Asset	0.0107
	Profit Margin	(0.02) %
	Operating Margin	0.11 %
	Current Valuation	3.07 B
	Shares Outstanding	77.5 M
	Shares Owned By Insiders	0.77 %
	Shares Owned By Institutions	99.23 %
	Number Of Shares Shorted	2.88 M
	Price To Earning	(10.61) X
	Price To Book	2.83 X
	Price To Sales	7.83 X
	Revenue	361.05 M
	Gross Profit	194.95 M
	EBITDA	(49.41 M)
	Net Income	(74.4 M)
	Cash And Equivalents	170.11 M
	Cash Per Share	2.37 X
	Total Debt	12.63 M
	Debt To Equity	0.02 %
	Current Ratio	4.09 X
	Book Value Per Share	15.18 X
	Cash Flow From Operations	44.22 M
	Short Ratio	3.58 X
	Earnings Per Share	(0.13) X
	Target Price	42.78
	Number Of Employees	815
	Beta	1.67
	Market Capitalization	3.33 B
	Total Asset	1.11 B
	Retained Earnings	(468.12 M)
	Working Capital	224.38 M
	Current Asset	47.91 M
	Current Liabilities	14.72 M
	Net Asset	1.11 B

About Veracyte Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Veracyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veracyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veracyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC